{"release":"wpf-flagship-weight-management","version":"1.4.0","resultsSha256":"7015f8dd771509f9548e11fe120b65641159173a214b88ed02a6a90183b4538e","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","WPF-authored verification records (verification): the locator descriptions, verification notes, automated-check descriptions and outcomes, the not-verified lists and WPF's paraphrased summary of the authors' stated limitations","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","Short quotations of third-party text inside verification records (quotedSourceText: registry outcome-measure titles and similar strings). They are marked as third-party","Third-party slide decks and other reproductions linked only as corroboration","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.4.0 (2026-11-14), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.4.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"retatrutide-phase2-weight-48w","candidateId":"retatrutide:2","kind":"separate_placebo_controlled","trial":"Retatrutide phase 2 (double-blind)","agents":"Retatrutide 1, 4, 8 or 12 mg vs placebo","pmid":"37366315","doi":"10.1056/NEJMoa2301972","registryId":"NCT04881760","population":"338 adults with BMI 30 or more, or 27 to under 30 plus at least one weight-related condition","comparator":"Placebo (multiple dose arms, 2:1:1:1:1:2:2 randomization)","endpoint":"Primary: percent change in body weight at 24 weeks. Secondary: at 48 weeks","followUp":"48 weeks (primary endpoint at 24 weeks)","result":"At 48 weeks: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% placebo","uncertainty":"Not reported in the abstract. ClinicalTrials.gov posts differences from placebo at week 48 (95% CI): 1 mg -6.57 (-8.94 to -4.20); 12 mg -22.11 (-24.92 to -19.31). The 4 mg and 8 mg groups are posted separately by starting dose.","discontinuation":"Handled by a hypothetical strategy: the primary (efficacy) estimand asks what the effect would be had participants adhered, and the registry's 48-week results use a model that excludes data after permanent discontinuation. Registry participant flow counts study completion, not stopping the drug: placebo 50 of 70, 1 mg 60 of 69, 4 mg 52 of 67, 8 mg 59 of 70, 12 mg 54 of 62 (by starting-dose arm). The registry posts no count of participants who stopped the drug and stayed in the study.","funder":"Eli Lilly","registryResultsPosted":true,"registryMasking":"Double","estimand":"Efficacy estimand: the plan's primary estimand, also applied to the 48-week secondary endpoint. Permanent discontinuation of study drug is handled by a hypothetical strategy, asking what the effect would be had participants adhered to treatment. The registry's 24- and 48-week results use a mixed-effects model that excludes data after discontinuation, consistent with this; the displayed 48-week values match the registry's secondary measure.","analysisPlan":{"title":"Retatrutide phase 2 Statistical Analysis Plan V4.0 (approved 15 Dec 2022), ClinicalTrials.gov NCT04881760","url":"https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf","sections":"§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach"},"limitations":["Phase 2 dose-finding trial of 338 adults split across seven arms, so each arm is small.","The primary endpoint was at 24 weeks; the 48-week results are secondary.","Funded by the manufacturer of retatrutide. A phase 3 outcome is not represented here."],"citation":"Retatrutide phase 2 (double-blind). Retatrutide 1, 4, 8 or 12 mg vs placebo. Primary source: https://doi.org/10.1056/NEJMoa2301972 (PMID 37366315; NCT04881760). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result retatrutide-phase2-weight-48w. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=retatrutide-phase2-weight-48w | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w","releaseVersion":"1.4.0","designLabel":"Separate placebo-controlled trial (not a head-to-head)","designExplanation":"This drug was compared with placebo in its own trial. Setting two trials side by side is an indirect comparison across different populations, durations and designs, so their percentages cannot be subtracted.","verification":{"verifiedOn":"2026-11-14","locators":[{"claim":"48-week least-squares mean change: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg) vs -2.1% (placebo)","source":"PubMed abstract","role":"primary","locator":"Abstract, Results paragraph: reports the 48-week least-squares mean percentage change for the 1 mg group, the combined 4 mg group, the combined 8 mg group, the 12 mg group and placebo, among 338 enrolled adults.","url":"https://pubmed.ncbi.nlm.nih.gov/37366315/#abstract","status":"matched","method":"scripted","checkId":"pubmed-retatrutide"},{"claim":"The same 48-week values in the registry","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT04881760, Results tab, first secondary outcome measure for mean percent change in body weight at week 48: placebo -2.11, 1 mg -8.67 and 12 mg -24.22; the 4 mg and 8 mg groups are posted as separate starting-dose arms (-16.32 and -17.83; -21.72 and -23.88).","url":"https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures","status":"matched","method":"scripted","checkId":"ctgov-retatrutide-w48","note":"The primary outcome (week 24) is outcome measure 1 in the registry; the week-48 measure is the first secondary.","quotedSourceText":["Mean Percent Change From Baseline in Body Weight"]},{"claim":"Uncertainty shown on this page: differences from placebo with 95% confidence intervals","source":"ClinicalTrials.gov results","role":"primary","locator":"Same outcome measure, statistical analyses: the 1 mg arm vs placebo posts a least-squares mean difference of -6.57 (95% CI -8.94 to -4.20); the 12 mg arm vs placebo posts -22.11 (95% CI -24.92 to -19.31).","url":"https://clinicaltrials.gov/study/NCT04881760?tab=results#outcome-measures","status":"matched","method":"scripted","checkId":"ctgov-retatrutide-diff-1mg","note":"These are differences from placebo, not confidence intervals around each arm's own mean. A second check covers the 12 mg row."},{"claim":"Primary estimand (efficacy; hypothetical strategy for permanent discontinuation) applies to the 48-week estimate","source":"Statistical analysis plan","role":"primary","locator":"SAP version 4.0 (15 Dec 2022): section 1.1 defines the primary estimand and the estimands for secondary objectives; section 4.3.2 describes the main analytical approach.","url":"https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf","status":"matched","method":"document_read","note":"The registry population excludes data after discontinuation of study drug, consistent with the hypothetical strategy."},{"claim":"Study completion by starting arm, which is how the registry reports leaving the study","source":"ClinicalTrials.gov results","role":"primary","locator":"Record NCT04881760, Results tab, participant flow, overall study period: 338 participants started across seven starting arms. Completed the study out of started: placebo 50 of 70, 1 mg 60 of 69, 4 mg 26 of 33 and 26 of 34 (52 of 67), 8 mg 30 of 35 and 29 of 35 (59 of 70), 12 mg 54 of 62. In the placebo arm 13 of the 20 who did not complete withdrew by their own choice. This counts leaving the study. It is not a count of stopping the study drug while staying in the study, which the registry does not post.","url":"https://clinicaltrials.gov/study/NCT04881760?tab=results","status":"matched","method":"scripted","checkId":"ctgov-retatrutide-flow"},{"claim":"Table or figure in the published paper that shows the displayed numbers","source":"Publisher page","role":"primary","locator":"Publisher article page reached through the DOI 10.1056/NEJMoa2301972","url":"https://doi.org/10.1056/NEJMoa2301972","status":"not_read","method":"document_read","note":"An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked; it does not show why. Europe PMC lists no open-access full text for this paper, and WPF has not established whether the article sits behind a paywall. No table or figure number is claimed."}],"unverified":["The table or figure in the published paper that shows these numbers: not located, because the publisher page could not be read.","Confidence intervals for the combined 4 mg and 8 mg groups: the registry posts them by starting-dose arm, so no source value for the combined groups was read.","Treatment-discontinuation counts (stopping the study drug but staying in the study): the registry participant flow reports study completion only, and the full text was not read.","The authors' own limitations and disclosure statements: not reviewed, because the full text could not be read."],"automatedChecks":[{"id":"ctgov-retatrutide-flow","what":"The registry participant flow posts the started and completed counts of all seven starting arms (338 started in total).","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 participant flow and compares the started and completed counts of every group.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pubmed-retatrutide","what":"The abstract reports all five displayed week-48 values and the sample size.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the PubMed record and compares the extracted abstract with the displayed values.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-retatrutide-w48","what":"The registry's week-48 measure posts the placebo, 1 mg and 12 mg values and the four starting-dose arm values.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): reads the ClinicalTrials.gov API v2 results record and compares posted values numerically.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"ctgov-retatrutide-diff-1mg","what":"The registry's analysis rows for 1 mg vs placebo (-6.57; -8.94 to -4.20) and 12 mg vs placebo (-22.11; -24.92 to -19.31) report the displayed estimates and both bounds, 95% two-sided.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): compares estimate and both bounds of each row numerically (the 12 mg row is check ctgov-retatrutide-diff-12mg).","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pooled-retatrutide-4mg","what":"The participant-weighted mean of the two registry 4 mg arms (33 and 33 participants) is consistent with the combined -17.1.","method":"WPF arithmetic in the same script; the source does not state this pooling.","outcome":"-17.07: consistent (2026-11-12)","lastRun":"2026-11-14"},{"id":"pooled-retatrutide-8mg","what":"The participant-weighted mean of the two registry 8 mg arms (35 and 35 participants) is consistent with the combined -22.8.","method":"WPF arithmetic in the same script; the source does not state this pooling.","outcome":"-22.80: consistent (2026-11-12)","lastRun":"2026-11-14"}],"humanReview":"none recorded"},"versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=retatrutide-phase2-weight-48w","analysisPlanUrl":"https://cdn.clinicaltrials.gov/large-docs/60/NCT04881760/SAP_001.pdf","analysisPlanSections":"§1.1 Primary estimand and estimands for secondary objectives; §4.3.2 main analytical approach","registryCheckedOn":"2026-11-11","detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#retatrutide-phase2-weight-48w"}}